", is how the IP ....will be divvy up between the lawyers, shareholders, regulators, and VCs.."
Given that FDA has thrice declined the application of drug,the value of the IP would be debatable...as the pipeline is variations of the same combinations..
Add to My Watchlist
What is My Watchlist?